Skip to main content

Table 3 Change in target lesion sum of longest diameters from post-chemotherapy baseline to post-chemotherapy nadir

From: A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer

Length of SLD Reduction (mm) BTH1677/
Bevacizumab/Carboplatin/
Paclitaxela
(N = 30)
Bevacizumab/Carboplatin/
Paclitaxela
(N = 13)
> 20 2 (7%) 0
> 10 6 (20%) 0
> 5 10 (33%) 2 (15%)
  1. Abbreviations: N overall sample size, SLD sum of longest diameters
  2. aNumber of patients continuing in study on maintenance therapy with at least 2 post-chemotherapy tumor assessments based on blinded central radiology review of the primary efficacy population